AR065901A1 - Derivados de pirrolipirimidina - Google Patents
Derivados de pirrolipirimidinaInfo
- Publication number
- AR065901A1 AR065901A1 ARP080101351A ARP080101351A AR065901A1 AR 065901 A1 AR065901 A1 AR 065901A1 AR P080101351 A ARP080101351 A AR P080101351A AR P080101351 A ARP080101351 A AR P080101351A AR 065901 A1 AR065901 A1 AR 065901A1
- Authority
- AR
- Argentina
- Prior art keywords
- 4alkyl
- optionally substituted
- groups
- ring
- atom
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 abstract 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 abstract 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07380088 | 2007-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065901A1 true AR065901A1 (es) | 2009-07-08 |
Family
ID=38475914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101351A AR065901A1 (es) | 2007-04-02 | 2008-03-31 | Derivados de pirrolipirimidina |
Country Status (16)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026107A1 (en) | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| AU2009244897B2 (en) | 2008-04-16 | 2014-11-13 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
| EP2271631B1 (en) * | 2008-04-22 | 2018-07-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| TW201024298A (en) * | 2008-09-23 | 2010-07-01 | Palau Pharma Sa | (R)-3-(N,N-dimethylamino)pyrrolidine derivatives |
| BRPI0922937A2 (pt) | 2008-12-05 | 2019-09-24 | Hoffmann La Roche | inibidores de pirrolopirazinil uréia quinase |
| HUE026518T2 (en) * | 2009-06-08 | 2016-06-28 | Takeda Pharmaceuticals Co | Dihydro-pyrrolo-naphthyridinone compounds as JAK inhibitors |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| CN102712658B (zh) * | 2009-10-29 | 2015-06-03 | 维克特拉有限公司 | 作为jak3激酶抑制剂的含氮杂芳基衍生物 |
| EP2590981B1 (en) * | 2010-07-09 | 2014-09-03 | Leo Pharma A/S | Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| CN103119045B (zh) * | 2010-08-20 | 2016-02-17 | 和记黄埔医药（上海）有限公司 | 吡咯并嘧啶化合物及其用途 |
| EP2611809A1 (en) * | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | Azolopyridine and azolopyrimidine compounds and methods of use thereof |
| WO2012030912A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
| BR112014012396B1 (pt) | 2011-11-23 | 2020-08-25 | Portola Pharmaceuticals, Inc | inibidores de pirazina quinase, composição, método in vitro para inibição de quinase syk ou via de transdução de sinal, uso dos referidos inibidores e kit |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| EP2947084B8 (en) * | 2013-01-18 | 2021-03-10 | Guangzhou Maxinovel Pharmaceuticals Co. | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof |
| KR101657616B1 (ko) * | 2013-05-24 | 2016-09-19 | 주식회사유한양행 | 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법 |
| CN106458914B (zh) * | 2014-03-28 | 2020-01-14 | 常州捷凯医药科技有限公司 | 作为axl抑制剂的杂环化合物 |
| CN105315285B (zh) * | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| NO2721710T3 (cg-RX-API-DMAC7.html) | 2014-08-21 | 2018-03-31 | ||
| CN105732636B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| CN113563342A (zh) | 2015-02-13 | 2021-10-29 | 达纳－法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
| CN104876934B (zh) * | 2015-05-12 | 2017-08-11 | 山东大学 | 一种含氮杂环苯基哌啶类化合物及其制备方法与应用 |
| BR112017025542A2 (pt) * | 2015-05-28 | 2018-08-07 | Theravance Biopharma R&D Ip, Llc | compostos de naftiridina como inibidores de quinase jak |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN120478294A (zh) | 2015-10-16 | 2025-08-15 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| AU2019223182B2 (en) | 2018-02-26 | 2021-08-19 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as HBV replication inhibitors |
| CN110526915B (zh) * | 2018-05-25 | 2022-02-01 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂的制备方法 |
| CA3118488A1 (en) | 2018-11-05 | 2020-05-14 | Avista Pharma Solutions, Inc. | Chemical compounds |
| US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| EP3955920A1 (en) | 2019-04-16 | 2022-02-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| KR20200133188A (ko) * | 2019-05-17 | 2020-11-26 | 보로노이바이오 주식회사 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
| CN110183471B (zh) * | 2019-05-21 | 2022-02-15 | 江苏大学 | 一种哌嗪类衍生物及制备方法及应用 |
| CN110317176A (zh) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
| CA3202990A1 (en) * | 2020-11-27 | 2022-06-02 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Aminoheteroaryl kinase inhibitors |
| CN116783198B (zh) * | 2020-12-02 | 2025-10-21 | 广东弘烨医药科技有限公司 | 螺环jak抑制剂、含其的药物组合物及其应用 |
| KR102666918B1 (ko) * | 2021-04-08 | 2024-05-20 | 주식회사 스탠다임 | 신규한 lrrk2 억제제 |
| WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
| CN119585254A (zh) * | 2022-06-29 | 2025-03-07 | 爱尔康公司 | 氮杂环丁烷基嘧啶及其作为jak抑制剂的用途 |
| CN118005609B (zh) * | 2022-11-09 | 2025-06-17 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| EA005852B1 (ru) * | 1998-06-19 | 2005-06-30 | Пфайзер Продактс Инк. | ПИРРОЛО[2,3-d]ПИРИМИДИНЫ |
| CA2596830A1 (en) * | 2005-02-03 | 2006-09-14 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrimidines useful as inhibitors of protein kinase |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
-
2008
- 2008-03-31 US US12/594,228 patent/US20110160185A9/en not_active Abandoned
- 2008-03-31 KR KR1020097020666A patent/KR20100015353A/ko not_active Withdrawn
- 2008-03-31 CA CA002682646A patent/CA2682646A1/en not_active Abandoned
- 2008-03-31 WO PCT/EP2008/053842 patent/WO2008119792A1/en not_active Ceased
- 2008-03-31 BR BRPI0809992-8A2A patent/BRPI0809992A2/pt not_active IP Right Cessation
- 2008-03-31 CN CN200880015843A patent/CN101679440A/zh active Pending
- 2008-03-31 AR ARP080101351A patent/AR065901A1/es not_active Application Discontinuation
- 2008-03-31 MX MX2009010595A patent/MX2009010595A/es not_active Application Discontinuation
- 2008-03-31 PE PE2008000586A patent/PE20090996A1/es not_active Application Discontinuation
- 2008-03-31 JP JP2010501495A patent/JP2010523522A/ja not_active Withdrawn
- 2008-03-31 RU RU2009140319/04A patent/RU2009140319A/ru not_active Application Discontinuation
- 2008-03-31 AU AU2008234822A patent/AU2008234822A1/en not_active Abandoned
- 2008-03-31 EP EP08735625A patent/EP2142550A1/en not_active Withdrawn
- 2008-04-01 CL CL200800946A patent/CL2008000946A1/es unknown
- 2008-04-01 TW TW097111869A patent/TW200904442A/zh unknown
-
2009
- 2009-09-21 IL IL201073A patent/IL201073A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100015353A (ko) | 2010-02-12 |
| PE20090996A1 (es) | 2009-07-15 |
| RU2009140319A (ru) | 2011-05-10 |
| CN101679440A (zh) | 2010-03-24 |
| JP2010523522A (ja) | 2010-07-15 |
| EP2142550A1 (en) | 2010-01-13 |
| US20110160185A9 (en) | 2011-06-30 |
| AU2008234822A1 (en) | 2008-10-09 |
| MX2009010595A (es) | 2009-10-22 |
| IL201073A0 (en) | 2010-05-17 |
| CL2008000946A1 (es) | 2008-10-10 |
| BRPI0809992A2 (pt) | 2014-10-14 |
| WO2008119792A1 (en) | 2008-10-09 |
| US20100113420A1 (en) | 2010-05-06 |
| CA2682646A1 (en) | 2008-10-09 |
| TW200904442A (en) | 2009-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065901A1 (es) | Derivados de pirrolipirimidina | |
| CL2016002942A1 (es) | Nuevos derivados de pirazolina pirimidina y su uso como inhibidores de malt1 | |
| AR064996A1 (es) | Derivados de purina | |
| PE20190337A1 (es) | NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| AR073397A1 (es) | Derivados de (r) -3- (n,n-dimetilamino) pirrolidina | |
| AR075975A1 (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ECSP10010473A (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización | |
| AR082109A1 (es) | Derivados de bipiridilo | |
| AR070079A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas con mtor quinasa y/o p13k | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR079690A1 (es) | Derivados heterociclicos de pirrol[2,3-b]piridina, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos como agentes anticancer. | |
| AR098147A1 (es) | Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico | |
| AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a | |
| AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
| ECSP11011201A (es) | Combinaciones que comprenden metotrexato e inhibidores de dhodh | |
| AR080056A1 (es) | Derivados de ciclohexil-amida como antagonistas de los receptores de crf | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |